Indacaterol/mometasone explained

Type:combo
Component1:Indacaterol
Class1:Beta-2 adrenergic receptor agonist
Component2:Mometasone
Class2:Corticosteroid
Tradename:Atectura Breezhaler, Bemrist Breezhaler
Routes Of Administration:Inhalation
Atc Prefix:R03
Atc Suffix:AK14
Legal Ca:Rx-only
Legal Ca Comment:[1]
Legal Eu:Rx-only
Legal Eu Comment:[2] [3] [4]
Legal Status:Rx-only
Kegg:D11862
Synonyms:QMF149, IND/MF

Indacaterol/mometasone, sold under the brand name Atectura Breezhaler among others, is a fixed-dose combination medication for the treatment of asthma in adults and adolescents twelve years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2 agonists.[5]

The most common side effects include worsening of asthma and nasopharyngitis (inflammation in the nose and throat). Other common side effects include upper respiratory tract infection (nose and throat infections) and headache. Indacaterol/mometasone was approved for medical use in the European Union in May 2020, and in Japan in June 2020.[6]

Notes and References

  1. Web site: Regulatory Decision Summary - Atectura Breezhaler . Health Canada . 23 October 2014 . 7 June 2022.
  2. Web site: Bemrist Breezhaler EPAR . European Medicines Agency . 24 March 2020 . 4 March 2023.
  3. Web site: Atectura Breezhaler Product information . Union Register of medicinal products . 3 March 2023.
  4. Web site: Bemrist Breezhaler Product information . Union Register of medicinal products . 3 March 2023.
  5. Web site: Atectura Breezhaler EPAR . European Medicines Agency (EMA) . 24 March 2020 . 23 June 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  6. Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options . Novartis . 29 June 2020 . 25 July 2020 . 26 July 2020 . https://web.archive.org/web/20200726035201/https://www.novartis.com/news/media-releases/novartis-receives-simultaneous-approval-five-new-products-from-japanese-ministry-health-labour-and-welfare-offering-japanese-patients-broad-range-novel . dead .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Indacaterol/mometasone".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.